Drug Trial Radar · NCT06072586
A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
82
Planned (sponsor's estimate)
Start
Oct 18, 2023
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- St. Joseph's Hospital and Medical Center, PhoenixAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ivy Brain Tumor Center; Barrow Neurological Institute
- First posted
- Oct 10, 2023
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will administer the investigational drug, BDTX-1535 to eligible patients with recurrent high-grade glioma (HGG) and newly-diagnosed glioblastoma (nGBM). BDTX-1535 was designed to block a growth signal important to some cancers. BDTX-1535 is being tested in this study to see if it can be given safely to people who have tumors that can be dependent on that growth signal because of changes in a protein called EGFR. These gene changes are called amplifications, mutations, fusions or alterations and are found only in the tumors. The study design includes a Phase 0 component with PK/PD-trigger for participant enrollment into an Expansion Phase 1 component. The primary objective of the Phase 0 component is to evaluate the PK endpoints of BDTX-1535. The primary objective of the Phase 1 component is to establish the safe dose of BDTX-1535 to be used in participants with a specified treatment regimen, three of which include standard of care radiotherapy for nGBM participants.
Conditions
- High Grade Glioma
- Glioblastoma
Interventions
BDTX-1535Drug
BDTX-1535 is an inhibitor of EGFR mutations
BDTX-1535 combined with radiation therapyDrug
During Phase 1, BDTX-1535 concurrently with standard of care upfront RT, followed by adjuvant monotherapy with BDTX-1535 continuously in 28-day cycles after RT.
BDTX-1535 combined with temozolomide and radiation therapyDrug
During Phase 1, BDTX-1535 concurrently with standard of care upfront RT and TMZ, followed by adjuvant BDTX-1535 combined with standard of care TMZ continuously in 28-day cycles after RT.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Unbound BDTX-1535 Concentration in Tumor TissueTime frame: Intraoperative
- Total BDTX-1535 Concentration in Tumor TissueTime frame: Intraoperative
- Incidence of DLTs ObservedTime frame: From day of first dose to the end of concurrent RT treatment at 10 weeks
- Number of Participants with Treatment-Emergent Adverse Events (TEAEs) as Assessed by NCI-CTCAE v5Time frame: Day of first dose until 30 days after final day of participation
- Number of Participants with Treatment-Related Adverse Events (TRAEs) as Assessed by NCI-CTCAE v5Time frame: Day of first dose until 30 days after final day of participation
- Number of Participants with Abnormal Laboratory Values as Assessed per NCI-CTCAE v5Time frame: Day of first dose until 30 days after final day of participation
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Chandler Regional Medical Center
Chandler, Arizona · Recruiting
St. Joseph's Hospital and Medical Center
Phoenix, Arizona · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.